First congressional hearing on 'Medicare for all' shows no signs of consensus on controversial issue

2 May 2019
house_of_representatives_big

The US House Committee on Rules held the first hearing on Medicare for all legislation this week, and, while the subject matter was familiar, the hearing itself was unusual, according to Stephanie Kennan of McGuireWoods Consulting.

Typically, the Rules Committee only holds hearings on bills that have gone through the appropriate authorizing committees, comments Ms Kennan. When asked about the break in procedure, Chairman McGovern (Democrat, Maryland) answered, “there is a new sheriff in town.” The House Budget Committee is expected to hold a hearing sometime in May as well – not unheard of, but also unusual.

Despite the procedural diversion, the subject matter and the hearing itself were reflective of the continued need to address the inequities of the US health care system, and the lack of universal coverage. Democrats were united in talking about the need for universal coverage, ignoring their differences on the issue itself. There were the “pro” witnesses, the “con” witnesses, and the patients with heartbreaking, compelling stories to remind us of the immorality of our health care system and how it works. The experience was reminiscent of the first hearings for the failed Clinton plan and the first hearings for what became the Affordable Care Act, noted Ms Kennan.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical